Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(3 sites)
United States
Clinical Pharmacology of Miami ( Site 0003), Miami, Florida Orlando Clinical Research Center ( Site 0001), Orlando, Florida Texas Liver Institute ( Site 0002), San Antonio, Texas